Literature DB >> 16704947

Use and costs of nonrecommended tests during routine preventive health exams.

Dan Merenstein1, Gail L Daumit, Neil R Powe.   

Abstract

BACKGROUND: Routine office visits for preventive health exams (PHEs) are designed to identify asymptomatic diseases at early treatable stages and influence healthy behaviors. Investigation included how often diagnostic tests and procedures were performed for which evidence and guidelines recommend against in asymptomatic individuals during routine PHEs, and the costs associated with the tests and procedures.
METHODS: In 2005, a cross-sectional study of office-based interventions was conducted, using National Ambulatory Medical Care Survey (NAMCS) data from 1997 to 2002. Recommendations from the United States Preventive Services Task Force (USPSTF) were used as a measure of appropriateness of diagnostic interventions during the PHE. Laboratory tests and procedures not recommended (D ranking) included urinalysis (UAs); interventions not recommended included electrocardiograms (EKGs) and x-rays.
RESULTS: The frequency of ordering any of the three diagnostic interventions ranged from 5% to 37%, and at least one of the interventions was ordered 43% of the time. Annual direct costs for the three interventions range from $47 million to $194 million.
CONCLUSIONS: Less use of unwarranted interventions will likely eliminate waste and improve the overall quality of health care in the United States.

Entities:  

Mesh:

Year:  2006        PMID: 16704947     DOI: 10.1016/j.amepre.2006.02.003

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  14 in total

Review 1.  Race/Ethnicity and overuse of care: a systematic review.

Authors:  Nancy R Kressin; Peter W Groeneveld
Journal:  Milbank Q       Date:  2015-03       Impact factor: 4.911

2.  Comparison between US Preventive Services Task Force recommendations and Medicare coverage.

Authors:  Lenard I Lesser; Alex H Krist; Douglas B Kamerow; Andrew W Bazemore
Journal:  Ann Fam Med       Date:  2011 Jan-Feb       Impact factor: 5.166

3.  Determinants of receipt of recommended preventive services: implications for the Affordable Care Act.

Authors:  Stacey McMorrow; Genevieve M Kenney; Dana Goin
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

Review 4.  Screening with urinary dipsticks for reducing morbidity and mortality.

Authors:  Lasse T Krogsbøll; Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

5.  Impact of periodic health examination on surgical treatment for uterine fibroids in Beijing: a case-control study.

Authors:  Hai-Yun Wu; Ling-Ling Yang; Shan Zhou
Journal:  BMC Health Serv Res       Date:  2010-12-07       Impact factor: 2.655

6.  Preventive health services implemented by family physicians in Portugal-a cross-sectional study based on two clinical scenarios.

Authors:  Carlos Martins; Luís Filipe Azevedo; Cristina Santos; Luísa Sá; Paulo Santos; Maria Couto; Altamiro Pereira; Alberto Hespanhol
Journal:  BMJ Open       Date:  2014-05-26       Impact factor: 2.692

7.  Clinical preventive services in Guatemala: a cross-sectional survey of internal medicine physicians.

Authors:  Juan E Corral; Lauren D Arnold; Erwin E Argueta; Akshay Ganju; Joaquín Barnoya
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

8.  Larger differences in utilization of rarely requested tests in primary care in Spain.

Authors:  Maria Salinas; Maite López-Garrigós; Emilio Flores; Joaquín Uris; Carlos Leiva-Salinas
Journal:  Biochem Med (Zagreb)       Date:  2015-10-15       Impact factor: 2.313

9.  Low rate of non-attenders to primary care providers in Israel - a retrospective longitudinal study.

Authors:  Dana Rosen; Sasson Nakar; Arnon D Cohen; Shlomo Vinker
Journal:  Isr J Health Policy Res       Date:  2014-04-25

10.  Survey data on Vietnamese propensity to attend periodic general health examinations.

Authors:  Quan-Hoang Vuong
Journal:  Sci Data       Date:  2017-10-03       Impact factor: 6.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.